Status:
COMPLETED
Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets
Lead Sponsor:
AbbVie
Conditions:
Rheumatoid Arthritis (RA)
Eligibility:
All Genders
15+ years
Brief Summary
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. RA can reduce the ability to perform everyday tasks. The purpose of this study...
Eligibility Criteria
Inclusion
- \- All participants treated with RINVOQ.
Exclusion
- \- Participants not taking RINVOQ.
Key Trial Info
Start Date :
April 24 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 15 2025
Estimated Enrollment :
4211 Patients enrolled
Trial Details
Trial ID
NCT04340115
Start Date
April 24 2020
End Date
August 15 2025
Last Update
November 17 2025
Active Locations (1017)
Enter a location and click search to find clinical trials sorted by distance.
1
Kanda Orthopedics & Rheumatology Clinic /ID# 238592
Gamagōri, Aichi-ken, Japan, 443-0101
2
Handa City Hospital /ID# 232198
Handa-shi, Aichi-ken, Japan, 475-0817
3
Handa City Hospital /ID# 244106
Handa-shi, Aichi-ken, Japan, 475-0817
4
Ichinomiya Orthopedic /ID# 226814
Ichinomiya-shi, Aichi-ken, Japan, 491-0032